Antineoplastic Agents, Combined
Showing 1 - 25 of >10,000
Tumors, Carcinoma, Squamous, Antineoplastic Agents Trial (Nivolumab Injection [Opdivo])
Not yet recruiting
- Neoplasms
- +2 more
- Nivolumab Injection [Opdivo]
- (no location specified)
Jul 19, 2023
Urothelial Carcinoma, Anlotinib, Urogenital Tumors Trial in Tianjin (Anlotinib, Cisplatin, Carboplatin)
Not yet recruiting
- Urothelial Carcinoma
- +6 more
- Anlotinib
- +3 more
-
Tianjin, ChinaTianjin Medical Unversity Second Hospital
Aug 30, 2021
Breast Cancer, Gynecologic Cancer, HNSCC Trial in Boston (STX-478, Fulvestrant)
Recruiting
- Breast Cancer
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital
Mar 13, 2023
Ovarian Tumors, Fallopian Tube Tumors, Tumors by Site Trial (Drug: Anlotinib, Drug: Carboplatin/Paclitaxel)
Not yet recruiting
- Ovarian Neoplasms
- +14 more
- Drug: Anlotinib
- Drug: Carboplatin/Paclitaxel
- (no location specified)
Mar 17, 2021
White Spot Lesion of Tooth Trial in El Cairo (Remin Pro, X Pur Remin, Fluoride varnish)
Completed
- White Spot Lesion of Tooth
- Remin Pro
- +2 more
-
El Cairo, EgyptAl-Azhar University
May 23, 2023
Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)
Recruiting
- Neoplasms
- +12 more
- Toripalimab
- +3 more
-
Nanjing, Jiangsu, ChinaJinling Hospital, Affiliated Hospital of Medical School, Nanjing
Oct 28, 2023
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma Trial in
Recruiting
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
-
Columbus, Ohio
- +9 more
Aug 1, 2022
Port Wine Stain Trial (Topical Antiangiogenic, Pulsed Dye Laser)
Withdrawn
- Port Wine Stain
- Topical Antiangiogenic
- Pulsed Dye Laser
- (no location specified)
Oct 28, 2022
Hepatocellular Carcinoma, Liver Tumors, Digestive System Tumors Trial in Chengdu (TACE combined with sorafenib and PD-1 mAb)
Recruiting
- Hepatocellular Carcinoma
- +7 more
- TACE combined with sorafenib and PD-1 mAb
-
Chengdu, Sichuan, ChinaSichuan Cancer Hospital and Research Institute
Sep 14, 2020
NSCLC, Antineoplastic Agents Trial in Edmonton (Experimental intervention)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents
- Experimental intervention
-
Edmonton, Alberta, CanadaCross Cancer Institute
May 23, 2022
Ovarian Tumors, Fallopian Tube Tumors, Endocrine Gland Tumors Trial in Nanjing (Niraparib, Bevacizumab)
Unknown status
- Ovarian Neoplasms
- +23 more
-
Nanjing, Jiangsu, ChinaJiangSu Cancer Hospital
Nov 8, 2020
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Lupus Nephritis, Remission, Safety Issues Trial in Nanjing (Methylprednisolone Injectable Suspension, Belimumab Injection,
Recruiting
- Lupus Nephritis
- +2 more
- Methylprednisolone Injectable Suspension
- +2 more
-
Nanjing, Jiangsu, ChinaJiong Zhang
May 8, 2023
Opioid Use, Anesthesia Morbidity Trial (PG-ANB performed at the outset of LSG, PG-ANB performed at the end of the LSG)
Not yet recruiting
- Opioid Use
- Anesthesia Morbidity
- PG-ANB performed at the outset of LSG
- PG-ANB performed at the end of the LSG
- (no location specified)
Dec 24, 2022
Hypercholesterolemia, Hyperlipidemia Trial in Beijing (SHR-1209 ;)
Active, not recruiting
- Hypercholesterolemia
- Hyperlipidemia
- SHR-1209 ;placebo
-
Beijing, Beijing, ChinaBeijing Anzhen Hospital, Capital Medical University
May 23, 2022
Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Enfortumab vedotin)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Enfortumab vedotin
-
Salt Lake City, UtahHuntsman Cancer Institute
Jan 24, 2023
Triple-negative Breast Cancer Trial in Bengbu (Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab)
Recruiting
- Triple-negative Breast Cancer
- Albumin-Bound Paclitaxel
- +2 more
-
Bengbu, Anhui, ChinaDepartment of Medical Oncology, First Affiliated Hospital of Ben
Mar 15, 2022
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)
Recruiting
- Leukemia
- +19 more
- CYNK-001
-
Denver, Colorado
- +9 more
Sep 9, 2022
Psoriasis Trial (308nm Excimer laser, Tazarotene Topical Gel, Betamethasone Valerate)
Not yet recruiting
- Psoriasis
- 308nm Excimer laser
- +2 more
- (no location specified)
Oct 15, 2022
Hormone Receptor Positive Breast Carcinoma, Breast Tumors, Tumors, Breast Trial in Italy (Liquid biopsy and CT scan)
Recruiting
- Hormone Receptor Positive Breast Carcinoma
- +6 more
- Liquid biopsy and CT scan
-
Bergame, Bergamo, Italy
- +6 more
Apr 13, 2023
Acute Myeloid Leukemia, MDS Trial in China (Fludarabine, busulfan and melphalan, Fludarabine and Busulfan)
Active, not recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Fludarabine, busulfan and melphalan
- Fludarabine and Busulfan
-
Fuzhou, Fujian, China
- +8 more
Aug 14, 2023
Reporting of AdVerse Events Associated With AnTicAncerRapy
Recruiting
- Cancer
- Antineoplastic and Immunomodulating Agents
-
Caen, Basse Normandie, FranceAlexandre Joachim
Jan 4, 2021
Urinary Bladder Tumors, Urologic Tumors, Urogenital Tumors Trial in Shanghai (tislelizumab and BCG)
Recruiting
- Urinary Bladder Neoplasms
- +5 more
- tislelizumab and BCG
-
Shanghai, Shanghai, ChinaRen Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Jun 10, 2021